You Have a Great Story
We Know How To Tell It
Bioscribe Account Leaders
Bioscribe is a leading life science public relations agency dedicated to supporting organizations that are advancing biotechnology, genomics, bioinformatics, molecular diagnostics, and molecular and synthetic biology. Founded in the San Francisco Bay Area in 1997, our team members are located in the metro areas of San Francisco, New York, Washington DC, Boston, as well as in the UK.
For more than 20 years, we have been a leading boutique PR agency working with companies that powered the Human Genome Project and cutting-edge start-ups that are innovating to unlock its value. We've helped launch first, second and third-generation DNA sequencing systems, molecular biology lab tools and automation solutions, bioinformatics software, single cell analysis solutions, molecular diagnostics, DNA forensics systems, next-generation biotherapeutics such as cell therapies, and vaccines.
Our senior PR consultants and writers bring decades of experience and expertise in the biotech, diagnostics, pharma, and life science research markets. In addition to previous large PR agency experience, our team members have built in-house communications teams and covered the industry as journalists and editors of leading publications.
Need help telling your story? Contact us at info [@] bioscribe.com
It's The Companies We Keep
Our clients include innovative start-ups powering the DNA revolution, biotherapeutics companies, life science technologists, and financiers of healthcare innovation.
Fueling advancements in cancer immunology, immunotherapy, and pathology research
Menlo Park, CA
Akoya Biosciences’ history represents the rapid advancement driving the field of multiplexed biomarker analysis and immunofluorescence tissue analysis. Today’s Akoya portfolio spans the spectrum from powerful tools for discovery of important biomarkers to clinical research applications.
Novel imaging agents for the diagnosis of neurodegenerative diseases
Alzeca is focused on developing novel targeted MRI imaging agents for the early diagnosis of Alzheimer’s disease and other neurodegenerative disorders. The company’s proprietary technology is based on nanoparticles that specifically bind to abnormal proteins that accumulate in the brain years before significant cognitive symptoms appear.
Applying biopharma rigor to the vast therapeutic potential of the endocannabinoid system
San Diego, CA
Artelo is dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system.
Harnessing the microbiome to treat skin disease
Azitra, Inc. is a preclinical stage biotechnology company combining the power of the microbiome with cutting-edge genetic engineering to treat skin disease.
Actionable strategies for life sciences
Bionest works to create competitive advantage for its clients by developing innovative and differentiated strategies at the corporate, portfolio and brand levels of medical and life science businesses. They also provide valuation and due diligence services to companies, investors and private equity.
Developing next-generation cell therapies
Basking Ridge, NJ
Caladrius is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases.
Next-generation single-cell analysis platform
Ann Arbor, MI
Celsee’s first product, the Genesis system, enables scientists to analyze and interpret cellular behavior and collect previously inaccessible information for improved results in applications such as proteogenomics, next-generation sequencing, immune monitoring, and cell therapy.
Cloud platform & global network
Mountain View, CA
DNAnexus® has built the world’s most secure, trusted cloud platform and global network for scientific collaboration and accelerated discovery. We partner with customers to tackle the world’s most exciting opportunities in human health and beyond.
Clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity
San Diego, CA
EpicentRx is a patient-driven oncology company developing new mechanisms of immunotherapy that work across diverse patient populations and tumor types with minimal toxicity, enabling the best-possible quality of life during treatment.
Access the living microbiome at unprecedented scale
San Carlos, CA
GALT is a leading developer of next-generation cultivation platforms for microbiome research and microbial product development, addressing high-impact markets including human health, agriculture, environmental science, and microbial products for industrial use.
Body-on-a-chip technology for toxicology and efficacy screening
Hesperos has develops a tool to characterize an individual’s biology with human-on-a-chip microfluidic systems. With a mission to revolutionize toxicology testing as well as efficacy evaluation for drug discovery, the company has created pumpless platforms with serum-free cellular mediums that allow multi-organ system communication and integrated computational modeling of live physiological responses of functional neurons, cardiac, muscle, and neuromuscular junctions as well as liver, pancreas and barrier tissues.
Clinical-stage biopharmaceutical company
HighTide Therapeutics is a global clinical-stage biopharmaceutical company focused on discovering and developing novel drugs to treat chronic liver diseases, gastrointestinal diseases and metabolic disorders with high unmet needs.
NGS tools for mass-scale population genetics, microbiome and synthetic biology studies
San Diego, CA
Scientists around the world use the company's RIPTIDE® High-Throughput Rapid Library Prep to maximize laboratory capacity and statistical power for applications in population genetics, agrigenomics, microbiome, and synthetic biology.
Inspiring genomic design
Inscripta is a gene-editing technology company that puts researchers in control by making it easy for them to get all they need for cutting-edge, forward cell-engineering. These tools include a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools.
Breakthrough solutions to improve health and advance science
Luminex aims to transform global healthcare and life science research through the development, manufacturing, and marketing of proprietary instruments and assays that deliver cost-effective, rapid results to clinicians and researchers.
Analytical detection devices for the next generation of rapid point-of-care diagnostics
Founded by physicists from the University of California-Berkeley and Lawrence Berkeley National Laboratory, Nanōmix is developing the next generation of mobile, point-of-care medical diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings. .
Unlocking the potential of exosome characterization
NanoView provides direct from sample, label-free characterization of extracellular vesicles with no purification required. The platform will assist in the translation of extracellular vesicle research into the clinical and therapeutic environment.
Aiding early detection of autism through metabolomics
Stemina markets its ASD diagnostics through its neurological disorders division, NeuroPointDX. Their metabolomics-based tool assists with the diagnosis of autism spectrum disorder and is also relevant to other neurological disorders that are notoriously difficult to diagnose and treat, including schizophrenia, depression, and anxiety.
Unleashing the Potential of Tau Oligomer Inhibition™
New York, NY
Oligomerix is an emerging biotechnology company focused on discovering and developing novel, small-molecule inhibitors of tau oligomer formation for Alzheimer’s disease (AD) and related neurodegenerative diseases with tau pathology.
Developers of hand-held, battery-operated molecular detection systems
Santa Cruz, CA
Ontera was founded with the idea that better information is needed to enhance human and environmental health in a sustainable way. The company aims to revolutionize diagnostics with its single-molecule detection and genome analysis platforms based on proprietary biochemistry and silicon nanopore chip-based sensors.
Investment bankers for middle market growth companies in life sciences
Wellesley, Mass and Reston, VA
Outcome Capital is a unique investment banking firm that provides middle-market growth companies in the life sciences, healthcare services and technology markets with a value-added client-centric approach to merger, acquisition and corporate finance advisory services.
Third-generation DNA sequencing for complex genomics projects
Menlo Park, CA
Pacific Biosciences in transforming the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research.
A revolution in DNA extraction
Purigen Biosystems is redefining nucleic acid sample preparation with an innovative platform based on the highly efficient isotachophoresis technology invented by a team of scientists at Stanford University.
Highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring
Resolution is dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world.
Health information company merging big data analytics with clinical diagnostics
Sema4 is a next-generation health information company, spun out of the Mount Sinai Health System, that provides advanced genomic testing and merges big data analytics with clinical diagnostics.
Creating the world's most advanced platform for local drug activation
San Francisco, CA
Shasqi, Inc., founded in 2018, is a privately held company focused on developing cancer treatments using bioorthogonal “click” chemistry for localized drug delivery. Shasqi’s treatments employ activating agents in an injected biomaterial to concentrate and activate systemic prodrug versions of cancer drugs directly at the tumor site.
Department of Translational Genomics
Los Angeles, CA
The Department of Translational Genomics brings to bear vast experience and expertise in molecular genetics, genome science, biomedical informatics, translational science, and molecular medicine.
Some of our past clients include:
Allakos • Aravive • Association for Molecular Pathology • Applied Biosystems • BD Biosciences • Benchling • Biotique Systems • Cellular Research • Chiron Corporation • Connetics • Cynvenio Biosystems • DNAnexus • DoubleTwist • Eos • Eurofins Genomics • Gen9 • GE healthymagination • Genentech • GenoSpectra • IDbyDNA • IntegenX • Invitrogen • Kapa Biosystems • Labcyte • Medcision • Microsoft Health Solutions • Medtronic • Mohr Davidow Ventures • NanoString Technologies • Nektar • Omicia • Osel • PAG • PaxVax • Personalis • Protagonist • QIAGEN Bioinformatics • RainDance Technologies • Sage Science • StationX • Tetra Therapeutics • twoXAR • Varian Medical Systems • VitaPath Genetics • Xcell Biosciences • Zyomyx
OUR CLIENTS IN THE NEWS
A sample of some of the stories we are helping to tell
President & CEO
Nicole founded Bioscribe in 1997 in San Francisco to meet the communications needs of the emerging biotech industry. She has more than 20 years experience providing PR counsel to Fortune 500 companies, small start-ups, and non-profit associations in this industry.
Senior Vice President
Joan is an industry veteran who started her career at Genentech in regulatory affairs and then became a biotech journalist before switching to the other side of the desk to provide strategic communications counsel to biotechnology companies, including efforts to support financing and corporate partnering initiatives.
Senior Vice President
Michelle has more than 20 years experience developing and managing strategic corporate communications, investor relations, and media relations programs for life sciences/healthcare companies. She was most recently VP of Corporate Communications at clinical-stage immuno-oncology company Agenus, Inc.
Prior to joining Bioscribe, Meredith was CEO and Editor-in-Chief of GenomeWeb, the leading news and information service for scientists in the systems biology field. Meredith is our head writer and leads the editorial strategy and content marketing programs for our clients.
Senior Vice President
Michele has more than 25 years of experience in healthcare public relations. Previously a senior vice president and director of MSLGroup’s West Coast healthcare practice, Michele currently provides communications services to pharmaceutical, biotechnology, and medical device/diagnostics companies through her own consultancy and as part of Bioscribe.
We are a small group of senior, self-directed professionals passionate about helping clients communicate stories about life science innovations. We are currently recruiting PR counselors, media relations pros, scientific marketing content writers and MarCom experts who have experience working on biotech accounts. Please send a copy of your resume to us at info [@] bioscribe.com. If it looks like a great match, we'll be in touch.